Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
Overview
AngioDynamics Inc is a Nasdaq-listed public company renowned for designing, manufacturing, and selling a broad portfolio of innovative medical devices that serve diverse clinical applications. With deep expertise in the fields of oncology, interventional radiology, and vascular surgery, the company focuses on the minimally invasive treatment of diseases such as peripheral vascular disorders and cancer. Industry-specific keywords such as "minimally invasive procedures", "diagnostic devices", and "interventional radiology" underscore the company’s commitment to technological innovation.
Core Business and Operations
The company operates by providing a comprehensive range of devices which include systems for radiofrequency ablation, vascular access, angiographic procedures, dialysis support, angioplasty, drainage, thrombolysis, embolization, and venous treatments. These products are designed for use in clinical settings by interventional radiologists, surgeons, and nephrologists. Through its diverse product line, AngioDynamics is able to offer end-to-end solutions that enhance procedural efficiency and patient outcomes. The revenue model primarily relies on direct sales to healthcare institutions, supported by a strong service network ensuring reliability and continued product support.
Market Position and Competitive Landscape
AngioDynamics has distinguished itself in a technologically competitive and high-growth industry. By investing in research and development, the company has maintained its ability to continuously bring forward new technologies and improve existing products. This commitment to innovation positions the company among notable competitors in the medical device industry. Its competitive differentiation stems from a consistent track record of product innovation, robust clinical performance, and strategic market presence. The company's market position is further bolstered by its focused approach to addressing specialized clinical needs and its ability to integrate advanced technological solutions into traditional treatment paradigms.
Product Portfolio and Technological Innovation
The product portfolio of AngioDynamics spans a wide range of medical device categories. From advanced radiofrequency ablation systems to precision surgical tools, the company leverages cutting-edge technology to develop devices that offer improved safety profiles and enhanced procedural outcomes. Emphasis on 'innovative technology' and 'minimally invasive procedures' highlights the company’s pursuit of excellence in device performance. Each product category is built on comprehensive clinical insights and a deep understanding of procedural requirements, ensuring that healthcare providers are equipped with devices that cater to their diagnostic and therapeutic needs.
Operational Excellence and Industry Expertise
AngioDynamics demonstrates operational excellence by aligning its product development with the evolving needs of healthcare providers. The company’s strategic focus on clinical innovation and rigorous quality control reflects its deep industry expertise and commitment to delivering reliable and effective medical solutions. Structured research programs, continuous product improvements, and a robust post-market support system underpin the company’s reputation for innovation and operational excellence. This integrated approach assists healthcare professionals in achieving improved outcomes while ensuring safety and compliance under constantly evolving medical standards.
Strategic Business Model and Value Proposition
Central to AngioDynamics' value proposition is the delivery of solutions that advance the standard of care in critical clinical procedures. The company’s business model is built around the continuous enhancement of product performance and the facilitation of minimally invasive therapeutic options. By maintaining a deep focus on quality and usability, AngioDynamics provides a reliable partnership for medical institutions seeking to integrate innovative device technologies. This strategic alignment with frontline clinical needs makes the company a noteworthy reference point for discussions on medical innovation, procedural efficiency, and enhanced patient care.
Industry Impact and Long-Term Relevance
With a rich history dating back to its founding in 1988, AngioDynamics has consistently contributed to medical advancements through its innovative product solutions. The company's impact on the healthcare industry is visible across multiple clinical areas, reinforcing its role as a significant player in medical technology. The enduring relevance of its products and the clarity of its market focus ensures that AngioDynamics remains a principal component in the discussion of medical device innovation and procedural technology. This comprehensive approach, combined with clear communication and expert-driven design, continues to shape the narrative around modern, efficient, and effective clinical practices.
AngioDynamics, Inc. (NASDAQ: ANGO) has announced that President and CEO Jim Clemmer, along with Executive VP and CFO Stephen Trowbridge, will present at the Needham 22nd Annual Virtual Healthcare Conference on April 17, 2023, at 8:00 a.m. ET. The presentation aims to showcase the company’s innovative medical technologies focused on enhancing blood flow and cancer treatment options, ultimately improving patient quality of life.
A live webcast will be available in the “Investors” section of AngioDynamics’ website, with a replay accessible post-event. The presentation highlights the company’s commitment to addressing unmet patient needs through its transformative medical solutions.
AngioDynamics reported third-quarter fiscal 2023 net sales of $80.7 million, a 9.1% increase from last year. Med Tech sales grew 16.6% to $22.9 million, driven by Auryon and NanoKnife products. However, gross margin decreased to 50.2%, down 200 basis points year-over-year. The company reported a net loss of $9.5 million or $0.24 per share, compared to a loss of $5.0 million a year ago. Adjusted EBITDA was $4.3 million, falling from $6.7 million in Q3 2022. Due to lower AngioVac sales, the fiscal 2023 guidance for net sales was revised downward to $338 million to $342 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its financial results for Q3 of fiscal year 2023 on
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced participation in three investor conferences in March 2023. The Raymond James Institutional Investors Conference will be held on
AngioDynamics (ANGO) reported a strong Q2 FY2023, with net sales of $85.4 million, a 9.1% increase year-over-year. Med Tech sales surged 29.7% to $24.5 million, driven by Auryon and NanoKnife products. However, the company posted a GAAP loss per share of $0.21, unchanged from the prior year. Gross margin increased to 52.8%, despite macroeconomic pressures like labor shortages. For H1 FY2023, net sales rose 7.5% to $167 million. AngioDynamics reaffirmed its FY2023 guidance for net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will present at the J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. This presentation focuses on AngioDynamics' commitment to transforming medical technology aimed at restoring vascular health and enhancing cancer treatment options. A live webcast will be available on the company's website, with a replay following the event.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its financial results for Q2 of fiscal year 2023 on January 5, 2023, before the market opens. A conference call with management will be held at 8:00 a.m. ET to discuss these results. Investors can participate by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and using the passcode 13734978. The call will also be webcast on the AngioDynamics website, with a replay available shortly after the call concludes.
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced that President & CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on November 30, 2022. The presentation will focus on the company's mission to enhance cancer treatment and restore healthy blood flow. Interested parties can access the live webcast through the Investors section of AngioDynamics' website, with a replay available post-event.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
What does AngioDynamics specialize in?
How does AngioDynamics generate its revenue?
What are the key product categories offered by AngioDynamics?
How does AngioDynamics differentiate itself from competitors?
Who are the primary customers of AngioDynamics?
What is the significance of minimally invasive procedures in their product development?
How does the company maintain its industry expertise?
What role does innovation play in AngioDynamics' business model?
